enGene Holdings Inc. (ENGN) Stock

enGene Holdings Inc. (ENGN) is a Healthcare stock trading at $1.72 (as of 2026-06-18), with a market capitalization of $123.93M and a trailing P/E of 4.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Valuation — source: SEC EDGAR (first-party)
Price	$1.72
Market Cap	$123.93M
P/E Ratio	4.1
EV / EBITDA	-0.6
Price / Book	0.45
Price / Sales	11.99
DCF Value (model)	$-24.85
DCF Upside vs Price	-1544.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$9.43M
Net Margin	-1244.5%
Return on Equity	-49.7%
Current Ratio	12.57
Revenue Growth (YoY)	-9.5%
EPS Growth (YoY)	56.8%
FCF Growth (YoY)	104.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	-1.94 (distress)

Valuation vs Sector & Industry
Stock P/E	4.1
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-80.4%
vs Industry	-75.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	FCPM III SERVICES B.V. ($65.60M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Ronald H. W. Cooper
Employees	56
Country	CA
IPO Date	2022-02-01

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.